Skip to content

Scholar Rock SRRK Return on equity

Return on equity at other companies

Biogen logo
BiogenBIIB
8%-1.2pp
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
-38.1%+13.4pp
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
-58.9%-4.4pp
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
24.5%-4.6pp
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
-85.7%+1.7pp
Arrowhead Research logo
Arrowhead ResearchARWR
-46.4%+341pp

Other financials

Income statement

See full
Revenue-
Operating income-$102.0M-32.3%
Net income-$105.5M-41.2%
EPS (diluted)-$0.83-23.9%

Balance sheet

See full
Cash & equivalents$430.5M+212%
Total debt$205.7M+226%
Total equity$276.0M-11.6%
Total assets$535.3M+31.3%

Cash flow

See full
Operating cash flow-$82.1M-4.4%
CapEx$68.0K-74.9%
Free cash flow-$82.2M-4.1%

Valuation

See full
Market cap$5.67B+85.5%

Profitability

See full
Operating margin-231.8%
Net margin-236.9%
FCF margin-309.1%

Returns & leverage

See full
Debt / equity0.7×+0.5×
Current ratio8.6×-1.6×

Where this comes from

Calculated from Scholar Rock’s reported figures.

Based on trailing twelve months.

The official record: Scholar Rock’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Scholar Rock's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Scholar Rock's return on equity?
Scholar Rock (SRRK) reported return on equity of -138.9% in Q1 2026.
How has Scholar Rock's return on equity changed year-over-year?
Scholar Rock's return on equity decreased by 30.2% year-over-year, from -106.7% to -138.9%.
What is the long-term trend for Scholar Rock's return on equity?
Over 5 years (2020 to 2025), Scholar Rock's return on equity has grown at a 21.6% compound annual growth rate (CAGR), from -46.3% to -123.1%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.